Investor Relations > details

Zensun Finished Patients Recruitment of rhNRG-1’s Phase II b Clinical Trial in China


After two years’ clinical study in China, Zensun’s genetically engineered ant-heart failure drug — rhNRG-1 has finished patients recruitment of Phase II b clinical trial.

In 2005, rhNRG-1 received SFDA approval to take phase II clinical study. Zensun finished Phase II a study in 2006 and started Phase II b in 2007. By the middle of December 2008, 237 patients have been recruited in our clinical study. So far, Zensun finished patients recruitment of rhNRG-1’s Phase II b clinical trial. The statistical analysis of clinical research data will be carried out in March next year. At the same time, Australian Phase IIa clinical study has been accomplished.